• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast

    7/18/24 10:12:11 PM ET
    $BEAM
    $GH
    $GTLB
    $TSLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $BEAM alert in real time by email

    On Thursday, Cathie Wood’s Ark Invest made a significant move by reducing its stake in Tesla Inc (NASDAQ:TSLA), despite a recent bullish outlook on the company’s potential in the autonomous taxi sector.

    The Tesla Trade

    The ARK Next Generation Internet ETF (NYSE:ARKW) sold 32,199 shares of Tesla, valued at approximately $8.02 million based on the closing price of $249.23 on the same day. This move comes after recent comments by Wood, who expressed her belief that Tesla’s stock could see a significant surge as it moves into the autonomous taxi business.

    Wood, in a recent Tiger Money podcast, stated that Tesla could potentially capture up to 50% of the autonomous taxi market, presenting a global revenue opportunity of $8 trillion to $10 trillion. She further emphasized that “Autonomous taxi platforms are the biggest AI project evolving today.”

    However, this isn’t the first time Ark Invest has trimmed its Tesla holdings. Earlier in July, Ark Invest began selling Tesla shares just after the company reported second-quarter deliveries that topped muted forecasts. The firm continued selling a smattering of its Tesla holdings over the next two sessions before pausing on last Monday.

    Other Key Trades:

    • Ark Invest’s Genomic Revolution ETF (ARKG) bought shares of Guardant Health Inc (NASDAQ:GH). The same fund also acquired shares of 10X Genomics Inc (NASDAQ:TXG).
    • Both ARKG and the flagship Ark Innovation ETF (ARKK) purchased shares of Beam Therapeutics Inc (NASDAQ:BEAM).
    • The ARKW fund also bought shares of GitLab Inc (NASDAQ:GTLB).

    Read Next:

    • As ‘Billionaire Boys’ Go All In For Trump, Anthony Scaramucci Has Word Of Caution: ‘Tonic They Are Prescribing Will Be Bad For America And The World’

    This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

    Get the next $BEAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAM
    $GH
    $GTLB
    $TSLA

    CompanyDatePrice TargetRatingAnalyst
    10x Genomics Inc.
    $TXG
    3/31/2026Mkt Perform → Outperform
    William Blair
    GitLab Inc.
    $GTLB
    3/23/2026Outperform → Underperform
    William Blair
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    GitLab Inc.
    $GTLB
    3/4/2026$28.00Overweight → Neutral
    Piper Sandler
    GitLab Inc.
    $GTLB
    3/2/2026$29.00Buy → Hold
    TD Cowen
    Beam Therapeutics Inc.
    $BEAM
    2/20/2026$74.00Buy
    Canaccord Genuity
    Guardant Health Inc.
    $GH
    2/20/2026$125.00 → $135.00Buy
    Canaccord Genuity
    Guardant Health Inc.
    $GH
    2/17/2026$120.00Outperform
    Robert W. Baird
    More analyst ratings

    $BEAM
    $GH
    $GTLB
    $TSLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tesla First Quarter 2026 Production, Deliveries & Deployments

    In the first quarter, we produced over 408,000 vehicles, delivered over 358,000 vehicles and deployed 8.8 GWh of energy storage products. Thank you to all of our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q1 2026   Production Deliveries Subject to operating lease accounting Model 3/Y 394,611 341,893 1% Other Models 13,775 16,130 2% Total 408,386 358,023 1% Tesla will post its financial results for the first quarter of 2026 after market close on Wednesday, April 22, 2026. At that time, Tesla will issue a brief advisory containin

    4/2/26 9:03:00 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

    Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31 Patients with SCD Demonstrated Deep Resolution of Red Blood Cell Dysfunction and Reduced Time in Hospital Driven by a Median of One Cell Collection Cycle and Rapid Engraftment U.S. Biologics License Application (BLA) Submission for risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the publication of data from

    4/1/26 5:12:19 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

    This milestone underscores the power of Guardant Health's InfinityAI platform and real-world data to enable innovative evidence generation in rare biomarker-defined populations Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive (HER2 [ERBB2] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers refractory or intolerant to standard treatments. This approval, granted by

    3/30/26 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    $BEAM
    $GH
    $GTLB
    $TSLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    10x Genomics upgraded by William Blair

    William Blair upgraded 10x Genomics from Mkt Perform to Outperform

    3/31/26 8:05:20 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    GitLab downgraded by William Blair

    William Blair downgraded GitLab from Outperform to Underperform

    3/23/26 8:26:40 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    BofA Securities resumed coverage on Tesla with a new price target

    BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00

    3/4/26 8:40:18 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $BEAM
    $GH
    $GTLB
    $TSLA
    SEC Filings

    View All

    Tesla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tesla, Inc. (0001318605) (Filer)

    4/2/26 9:07:13 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SEC Form S-8 filed by GitLab Inc.

    S-8 - Gitlab Inc. (0001653482) (Filer)

    3/30/26 5:57:15 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    SEC Form 144 filed by GitLab Inc.

    144 - Gitlab Inc. (0001653482) (Subject)

    3/27/26 5:22:39 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    $BEAM
    $GH
    $GTLB
    $TSLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $BEAM
    $GH
    $GTLB
    $TSLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BEAM
    $GH
    $GTLB
    $TSLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Evans John M.

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/6/26 5:48:48 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Simon Amy

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/6/26 5:44:35 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Bellon Christine

    4 - Beam Therapeutics Inc. (0001745999) (Issuer)

    4/6/26 5:39:44 PM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Staples William bought $124,750 worth of shares (3,276 units at $38.08), increasing direct ownership by 0.96% to 345,671 units (SEC Form 4)

    4 - Gitlab Inc. (0001653482) (Issuer)

    1/5/26 6:26:25 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    CEO Musk Elon bought $999,959,042 worth of shares (2,568,732 units at $389.28) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    9/15/25 6:01:19 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Director Gebbia Joseph bought $1,025,232 worth of shares (4,000 units at $256.31) (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    4/28/25 6:45:17 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    $BEAM
    $GH
    $GTLB
    $TSLA
    Financials

    Live finance-specific insights

    View All

    Tesla First Quarter 2026 Production, Deliveries & Deployments

    In the first quarter, we produced over 408,000 vehicles, delivered over 358,000 vehicles and deployed 8.8 GWh of energy storage products. Thank you to all of our customers, employees, suppliers, shareholders and supporters who helped us achieve these results. Q1 2026   Production Deliveries Subject to operating lease accounting Model 3/Y 394,611 341,893 1% Other Models 13,775 16,130 2% Total 408,386 358,023 1% Tesla will post its financial results for the first quarter of 2026 after market close on Wednesday, April 22, 2026. At that time, Tesla will issue a brief advisory containin

    4/2/26 9:03:00 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

    Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up Corrected M-AAT Comprised 94% of Total AAT with a Concomitant 84% Reduction in Mutant Z-AAT Following BEAM-302 60 mg Treatment Post-treatment Inducibility of AAT Observed During Respiratory Infection with a Patient Reaching ~30 µM Total AAT, Retaining 95% M-AAT Composition Well-tolerated Safety Profile Observed with Single Doses of BEAM-302 up to 75 mg; Safety Consistent Across Single-dose Part A and Part B Cohorts 60 mg Selected as Optimal Biological Dose, Supported by Strong Safety and E

    3/25/26 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GitLab Reports Fourth Quarter and Full Year Fiscal Year 2026 Financial Results; Board of Directors Authorizes $400 million for Share Repurchase Program

    Fourth Quarter Fiscal Year 2026 Highlights: Total revenue of $260.4 million, up 23% year-over-year GAAP operating margin of (2)%; non-GAAP operating margin of 21% Operating cash flow of $45.8 million and non-GAAP adjusted free cash flow of $41.8 million Fiscal Year 2026 Highlights: Total revenue of $955.2 million, up 26% year-over-year GAAP operating margin of (7)%; non-GAAP operating margin of 17% Operating cash flow of $232.9 million and non-GAAP adjusted free cash flow of $219.6 million -All-Remote-GitLab Inc. (NASDAQ:GTLB), the intelligent orchestration platform for DevSecOps, today reported financial results for its fourth quarter fiscal year of 2026, ended Janu

    3/3/26 4:05:00 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    $BEAM
    $GH
    $GTLB
    $TSLA
    Leadership Updates

    Live Leadership Updates

    View All

    GitLab Appoints Siva Padisetty as Chief Technology Officer

    Veteran engineering leader brings two decades of experience scaling cloud platforms and modernizing enterprise systems All-Remote - GitLab Inc., the most comprehensive intelligent DevSecOps platform, today announced the appointment of Siva Padisetty as Chief Technology Officer, effective January 15, 2026. Padisetty will lead GitLab's software engineering, operations, and customer support teams to execute the company's technical vision and strategy and oversee the development and delivery of GitLab's products. He succeeds Sabrina Farmer, who stepped down from her role and will remain in an advisory capacity to ensure a seamless transition through January 31, 2026. This press release featu

    1/12/26 9:05:00 AM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    Scientists Pointing to Hidden Power Source That Could Reshape Future of AI

    This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement. AUSTIN, Texas, Dec. 03, 2025 (GLOBE NEWSWIRE) -- MiningNewsWire: Global electricity demand is reaching a pivotal turning point. The International Energy Agency (IEA) now projects that global data-center electricity use will almost double by 2030, with AI-focused facilities increasing their consumption more than four times over the same span — a trajectory pushing power grids in the United States, China, Europe, Southeast Asia and other regions to their limits. The bottleneck is no longer data throughput or semiconductor performance; the critical constraint has become electricity it

    12/3/25 8:30:00 AM ET
    $AMZN
    $AVGO
    $META
    Catalog/Specialty Distribution
    Consumer Discretionary
    Semiconductors
    Technology

    GitLab Appoints Jessica Ross As Chief Financial Officer

    All Remote, GitLab Inc. (NASDAQ:GTLB), the most comprehensive, intelligent DevSecOps platform, today announced the appointment of Jessica Ross as chief financial officer, effective January 15, 2026. Ross succeeds Interim CFO James Shen, who will return to his role as vice president of finance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202385769/en/Jessica Ross Ross' appointment comes as GitLab continues to see strong momentum, achieving 25% revenue growth in the third quarter of fiscal year 2026. She will oversee GitLab's global finance, accounting, and investor relations functions as the company accelerates DevSecOps inn

    12/2/25 4:06:00 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    $BEAM
    $GH
    $GTLB
    $TSLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GitLab Inc.

    SC 13G/A - Gitlab Inc. (0001653482) (Subject)

    11/14/24 4:58:57 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by GitLab Inc.

    SC 13G/A - Gitlab Inc. (0001653482) (Subject)

    11/14/24 4:15:50 PM ET
    $GTLB
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care